Sherene Loi, MBBS, PhD, FRACP, FAHMS, Peter MacCallum Cancer Centre at the University of Melbourne, Melbourne, Australia, outlines how genomics can inform treatment approaches in triple-negative breast cancer (TNBC). Prof. Loi discusses how mutational status in certain genes can predict treatment responses, such as the well-known breast cancer susceptibility genes, BRCA1 and BRCA2, which predict responsiveness to PARP inhibitors. Other rarer mutations are also under investigation. Additionally, immunohistochemistry testing for HER2 plays a critical role in treatment planning. As new treatments emerge, additional impactful genomic factors are surfacing. This interview took place during the 17th St. Gallen International Breast Cancer Conference.
Research funding to institution: Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics Astra Zeneca, Roche-Genentech, Seattle Genetics. Consultancy (not compensated): Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca, Roche-Genentech. Consultancy (paid to institution): Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Seattle Genetics, Bristol Meyers Squibb. Scientific Advisory Board Member: Akamara Therapeutics. Supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York.